Silence Therapeutics (SLN) Research & Development (2024 - 2026)

Silence Therapeutics has disclosed Research & Development across 3 years of filings, most recently posting $9.1 million for Q1 2026.

• Research & Development for Q1 2026 came in at $9.1 million, down 56.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $75.0 million (up 63.65% YoY), and the FY2025 annual result was $67.8 million, up 57.93% from the prior year.
• Research & Development came in at $9.1 million for Q1 2026 at Silence Therapeutics, down from $27.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $27.7 million in Q4 2025 to a low of -$2.9 million in Q4 2024.
• The 3-year median for Research & Development is $17.6 million (2025), against an average of $14.1 million.
• Across the five-year window, Research & Development soared 1053.89% in 2025 and plunged 56.17% in 2026, its largest moves.
• Silence Therapeutics' Research & Development stood at -$2.9 million in 2024, then jumped by 1053.89% to $27.7 million in 2025, then tumbled by 67.07% to $9.1 million in 2026.
• The last three Research & Development figures came in at $9.1 million (Q1 2026), $27.7 million (Q4 2025), and $20.5 million (Q3 2025), per Business Quant data.